Clinical and pharmacological effects of treatment with a new antidepressant.
The novel tetracyclic piperazino-azepine compound Org GB 94 (Tolvon, Tolvin) in a dose of 20 mg three times daily was found to be of save markedly and significantly less side-effects. Patients with reactive depression and those with endogenous depression reponded equally well to Org GB 94. No correlation was found between plasma levels of Org GB 94 and either clinical effects or side-effects. Org GB 94 did not alter the tyramine pressor response, in contrast to amitriptyline.